Physician profile
Brooke Corbett
NPI 1962935825
$5,036.20
in general payments reported to CMS, 2019-2025
24 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $72.00 · 2021: $101 · 2022: $1,080 · 2023: $981 · 2024: $1,109 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.14 |
| Education | $363.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,400.45 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $874.57 | 2019-2025 | Tremfya |
| Ucb, INC. | $392.24 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $391.46 | 2023-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $225.61 | 2023-2025 | Opdivo, Sotyktu |
| Genzyme Corporation | $225.49 | 2023-2025 | |
| Pfizer INC. | $192.89 | 2022-2024 | |
| Lilly USA, LLC | $168.63 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $163.96 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $142.61 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.78 | 2022-2023 | Spevigo |
| Journey Medical Corporation | $123.54 | 2022 | |
| Allergan, INC. | $115.35 | 2022 | |
| Novo Nordisk INC | $110.64 | 2023 | |
| Merz North America, INC. | $56.25 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $52.86 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $44.11 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $42.92 | 2022-2025 | |
| Incyte Corporation | $41.34 | 2024-2025 | Opzelura |
| Amgen INC. | $37.06 | 2022-2025 | Otezla |
| Revance Therapeutics, INC. | $35.66 | 2025 | Daxxify |
| Biofrontera INC. | $28.61 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $24.82 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $15.35 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.